Cancer cells balance with the equilibrium of cell death and growth to expand and metastasize. The activity of mammalian sterile20-like kinases MST1/2 has been linked to apoptosis and tumor suppression via YAP/Hippo pathway dependent and independent mechanisms. With a kinase substrate screen we identified here MST1 and MST2 among the top substrates for fibroblast growth factor receptor 4 (FGFR4). In COS-1 cells, MST1 was phosphorylated at Y433 residue in an FGFR4 kinase activity-dependent manner, as assessed by mass spectrometry. 
Introduction
Cancer cells rely on oncogenic signaling by receptor tyrosine kinases (RTKs) to drive tumor initiation and progression [1] . When altered upon tumor evolution, RTKs contribute to the development of resistance towards initially effective anti-cancer treatments. Due to inhibitable enzyme activity and cell surface localization, RTKs thus serve as attractive targets for therapy. Fibroblast growth factor receptors (FGFRs) are RTKs that trigger a series of intracellular signaling cascades that can control key cellular processes including survival, proliferation, differentiation, and migration/invasion, as well as angiogenesis -each abnormally regulated in cancer [2] . Four homologous FGFRs are expressed in humans [2] . Unlike the other family members, FGFR4 is dispensable for normal development in mice [3] . This coupled with specific FGFR4 induction in certain cancers, as well as structural differences and drug selectivity relative to other FGFRs, supports the possibility of effective FGFR4 targeting as a therapeutic intervention [4] [5] [6] [7] [8] [9] .
Despite advances in diagnosis and treatment, subsets of breast cancer remain challenging to cure accounting for an estimated 15% of all cancer deaths in women (World Cancer Report, WHO 2014).
Like in other cancers, the poor prognosis is partially attributed to therapy resistance and anti-apoptosis responses of the cancer cells [10] . FGFR4 overexpression and gene alterations, including G388R single nucleotide polymorphism (SNP), have been associated with cancer invasion, drug resistance and poor prognosis [11] [12] [13] . Among breast cancers, FGFR4 is overexpressed in a significant proportion of especially HER2-enriched tumors [4] , where it has been linked to tumor cell growth and apoptosis resistance [4, 5, 14] . Despite these results, the molecular mechanisms how FGFR4 confers the aggressive cancer cell behavior remain incompletely understood.
In this study, we systematically screened for FGFR4 substrates using an in vitro human kinase substrate protein microarray. Unexpectedly, Hippo tumor suppressor pathway components, including the serine/threonine kinases MST1/2 (mammalian sterile20-like kinases), were among the most prominent tyrosine-phosphorylated substrates for FGFR4. Cytoplasmic MST1/2 comprises the core kinase complex of the mammalian Hippo pathway, which activation ultimately leads to serine phosphorylation-dependent cytoplasmic retention and inactivation of the oncogenic transcriptional regulators, YES-associated protein (YAP1) and transcriptional co-activator with PDZ-binding motif (TAZ) [15, 16] . Upon cell stress and apoptosis, caspase-3 cleavage in turn removes the inhibitory Cterminal domains of MST1/2 to induce transport of the activated N-terminal MST1/2 into the nucleus [17] . Although results from overexpression experiments have shown that nuclear MST1/2 can promote apoptosis [18] [19] [20] [21] , and reduced MST1/2 serine/threonine kinase activity has been linked to poor cancer prognosis [22] [23] [24] [25] , the functional contribution of endogenous MST1/2 in physiological or pathological apoptotic processes have remained elusive [17] . Our screening results led us to investigate in more detail the putative direct functional interaction of FGFR4 and MST1/2.
Altogether, these results establish a unique mechanism of oncogenic signaling -the dominant FGFR4-mediated attenuation of MST1/2-mediated, stress-associated apoptosis in HER2 + breast cancer.
Materials and Methods

Kinase Substrate Identification Array
For in vitro FGFR4 substrate identification, the protein microarray containing 9483 human recombinant proteins (Protoarray human protein microarrays version 5.0; Invitrogen), was blocked and incubated with the recombinant kinase domain of FGFR4 (50 nM; Invitrogen) in the presence of [γ-33P] ATP. The array was washed to remove unbound γ-33P, and exposed to X-ray film. The acquired array image was analyzed using ProtoArray Prospector software (Invitrogen). The raw data were subjected to background subtraction, signal scatter compensation, and outlier detection. The Z factor cutoff value was set at ≥0.4. Phosphorylated proteins with a Z score > 0.25 were considered as potential substrates.
Cell Culture
Human ZR-75.1, MCF7, BT474, T47D, MDA-MB-453, Hs578T, BT549, MDA-MB-231 (American Type Culture Collection; ATCC) and SUM159 [26] breast carcinoma cells, and COS-1 cells (ATCC)
were cultured according to manufacturer's instructions. The MycoAlertPlus kit (LT07-705, Lonza) was used for confirming the cell cultures negative for mycoplasma.
Antibodies, inhibitors and growth factors
The antibodies used were as follows: mouse monoclonal antibodies against ERBB2/HER2 (MA5- Flag epitope (N-terminal)-tagged MST1 and MST2 in the p3FLAG-CMV-10wt (Sigma-Aldrich) expression vectors have been described previously [27] . MST1 Y433F mutant was generated by sitedirected mutagenesis. FGFR4 and its kinase activity-deficient mutant (K503M) were cloned into pcDNA3.1/V5-His vector, and the expression vector for FGFR4 G388 variant was generated from R388 variant by site-directed mutagenesis [28, 29] . siRNAs used were SMARTpool siGENOME (Dharmacon, GE Healthcare) against human STK3 (MST2; L-004874), STK4 (MST1; L-004157) and nontargeting control siRNA (D-001206-14-10), as well as siRNAs against FGFR4 (ONTARGETplus siRNA pool, L-003134 Dharmacon, GE Healthcare; or SI02665306 (siFGFR4_6) and SI00031360 (siFGFR4_2), Qiagen).
Short hairpin RNA (shRNA) targeted against FGFR4 (TRCN0000000628, TRCN0000010531 and TRCN0000199510; Open Biosystems, GE Healthcare) or nontargeting scrambled shRNA were used.
The packaging plasmid (pCMVdr8.74), envelope plasmid (pMD2-VSVG), and FGFR4 or scrambled shRNA in pLKO.1 vector were co-transfected into 293FT producer cells using Lipofectamine 2000 reagent (Invitrogen). Complete breast carcinoma cell growth medium was changed on 293FT cells 24 hours after transfection. The viral supernatants were collected after 48 hours, passed through a 0.45-µm filter, and incubated with human breast carcinoma cells. After 16 hours of infection, the supernatants were replaced with complete media followed by puromycin (2 µg/ml) selection of the transduced cells [30] .
Cell transfections, sphere preparation and treatments
The cells were transfected with expression vectors using FuGENE HD (Promega, Madison, WI) and siRNAs using Lipofectamine 2000 (Invitrogen) or Interferin (Polyplus-transfection SA). Knockdown efficiencies were analyzed by Western blotting after 72 hours. For 2D immunofluorescence, cells were seeded on monomeric collagen coated (type I, 50 μg/ml, Sigma-Aldrich) coverslips, fixed in 4% paraformaldehyde (pH 7.5) , and stained as previously described [31] , and mounted in Vectashield with 4′,6-diamidino-2-phenylindole (DAPI; Vector Laboratories).
Spheres of 24 000 cells were allowed to form under nonadherent conditions in agarose-coated 96-well plates in cell culture media supplemented with 0.2 mg/ml Matrigel (growth factor reduced;
Corning) and cultured for 5-8 days [32] . The spheres were cultured in the indicated serum concentrations, or serum-starved for 16 hours before inhibitor treatment, followed by lysis with RIPA buffer. For immunofluorescence, the spheres were fixed in 4% paraformaldehyde (pH 7.5), post-fixed in ice-cold acetone-methanol (1:1) solution, incubated in blocking buffer (5% BSA, 0.1% Triton X-100 in PBS) and stained for MST1. Nuclei were visualized with Hoechst 33342 stain (Thermo Fisher Scientific). The spheres were mounted on glass slides in Vectashield (Vector Laboratories). At least two different cell lines and two independent cultures per stable lentiviral shRNA transduction were analyzed for MST1.
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were performed as described previously [33] . 
Mass spectrometry analysis of phosphorylation sites
All buffers of immunoprecipitation and elution procedures were supplemented with Complete protease inhibitor cocktail and PhosSTOP phosphatase inhibitor tablets (Roche). After the general immunoprecipitation washes, the anti-FLAG affinity gel was washed with pre-urea wash buffer (50 mM Tris pH 8.5, 1 mM EGTA, 75 mM KCl) before elution with urea buffer (6M Urea, 20 mM Tris pH 7.5, 100 mM NaCl). Elution cycles were repeated three times for 30 minutes each at RT with agitation. Proteins in eluates were reduced with (tris(2-carboxyethyl)phosphine), alkylated with iodoacetamide, and trypsin digested with Sequencing Grade Modified Trypsin (Promega).
Phosphopeptide enrichment was performed using immobilized metal ion affinity chromatography with titanium (IV) ion (Ti4+-IMAC). IMAC material was prepared and used essentially as described [34] . The LC-MS/MS analysis was performed using a Q Exactive ESI-quadrupole-orbitrap mass spectrometer coupled to an EASY-nLC 1000 nanoflow LC (Thermo Fisher Scientific), using Xcalibur Carbamidomethylation (+57.021 Da) of cysteine residues was used as static modification.
Phosphorylation of Ser/Thr/Tyr (+79.966 Da) and oxidation (+15.994 Da) of methionine was used as dynamic modification. Precursor mass tolerance and fragment mass tolerance were set to less than 15 ppm and 0.05 Da, respectively. A maximum of two missed cleavages was allowed. The software phosphoRS [35] was used to calculate the invidual site probabilities for phosphorylated peptides.
Flow cytometry analysis of apoptosis
The proportions of apoptotic cells were determined by flow cytometry for annexin V and propidium iodide binding [36] . The MST1 and YAP-stained sphere images were analyzed using Anima [37] . Cell nuclei were detected from DAPI channel by first normalizing images with adaptive histogram equalization, and then using the Shape filtering segmentation method found in Anima. The MST1 or YAP signal intensity values were measured from the nucleus area and from a ring around the nucleus representing the cytoplasm. The ring width was determined as 50% of the radius of the nucleus. The nucleus/cytoplasm intensity ratio was calculated by dividing nuclear intensity with cytoplasmic intensity for each nucleus, and then calculating a median value for each image.
Statistics
All numerical values represent mean ± SD or SEM as indicated in figure legends. Statistical significance was determined using two-tailed alone or in combination with FGFR4 G388 (G) or the cancer-associated R388 (R) SNP variant.
Notably, both variants induced tyrosine phosphorylation of MST1 and MST2, establishing these Hippo kinases as novel FGFR4 substrates (Fig. 1C) . Importantly, the FGFR4 (R)-mediated MST1/2 tyrosine phoshorylation was not detected after co-transfection with kinase activity-dead FGFR4 (R) KD (Fig. 1D ).
To identify the FGFR4 phosphorylated tyrosine residue(s), the immunoprecipitated MST1 was subjected to mass spectrometry (Fig. S1A) . Notably, MST1 derived from the FGFR4 expressing COS-1 cells was phosphorylated at Y433, whereas MST1 from the cells with inactive FGFR4 KD lacked tyrosine phosphorylated residues (Fig. 1E , Table 1 ). Additionally, an uncharacterized MST1 phosphorylation at S410 near the pY433-site was detected in the absence of FGFR4 kinase activity (Fig. 1E , Table 1 ), whereas phosphorylation of MST1 S320 and T177 appeared independently of FGFR4 activity (Table 1) .
FGFR4 is overexpressed in HER2 + breast cancer cells and correlates with adverse outcome in
HER2-enriched breast cancer patients. To investigate the clinical relevance of the identified novel FGFR4 activity, and to establish relevant cell models, we first analyzed FGFR4 expression using TCGA by cBioPortal for Cancer Genomics [38, 39] . In breast cancer, FGFR4 was overexpressed in 33% of the HER2-enriched tumors (PAM50 classified, n=58 [40] , and significantly associated with poorer overall survival as compared to the non-overexpressing group ( Fig. S1B ; P = 0.044; FGFR4
overexpression in 4% of all breast cancers; TCGA, n=825 [4] (Fig. 3A) , and the whole cell population for quantification of combined early and late apoptotic cells by double-positivity ( Fig. 3B, C ; annexin V + PI). Stable FGFR4 silencing significantly increased apoptosis relative to the control ( Fig. S3A; P≤0.02 and Fig. 3A-C) . Similarly, FGFR4 siRNAs increased apoptosis in shScr cells ( Fig. 3A-C; P<0.001 in C). MST1 or MST2 knockdown did not decrease apoptosis, and even slightly increased apoptosis in shScr cells with high endogenous FGFR4 (Fig. 3A-C) . Notably, while FGFR4 siRNAs did not further increase apoptosis in shFGFR4 cells (Fig. 3A-C) , the apoptosis induction caused by the stable FGFR4 silencing was rescued close to the low level of shScr cell apoptosis by knockdown of MST1 (Fig. 3A-C, P=0 .02 in C) or MST2 ( Fig. 3A-C 4B ). During this short term FGFR4 inhibition FRS2α was diminished, whereas pAKT and pERK remained almost unaffected (Fig. 4B) , linking FGFR4 activity directly to MST1 regulation.
Moreover, as assessed by immunofluorescence of the MDA-MB-453 and ZR-75.1 spheres, shScr cells had low nuclear and cytoplasmic MST1, whereas FGFR4 silencing increased MST1 specifically in the nuclei, significantly increasing the nucleus/cytoplasm intensity ratio (Fig. 4C, D, S3B ).
Altogether these results suggest that FGFR4 suppresses MST1/2 activation and MST1 nuclear localization to counteract apoptosis. (Fig. 4E) . Phosphorylation of MOB1 was also increased relative to total MOB1 in cells co-transfected with MST1-Y433F and FGFR4 (R) (Fig. 4E) . These results further indicate that FGFR4-dependent MST1 phosphorylation at Y433 suppresses MST1/2 activation in the FGFR4 expressing cancer cells.
Mutation of the site for FGFR4-mediated tyrosine phosphorylation restores
FGFR4 overexpression is associated with reduced YAP phosphorylation in breast cancer cell spheres and human tumors.
Apart from the pro-apoptotic nuclear activities, MST1/MST2 function as core Hippo pathway kinases [16, 17] . To test if the FGFR4-dependent suppression of MST1/2 activation alters this canonical Hippo tumor suppressor axis, we analyzed YAP S127 phosphorylation and localization in 2D and 3D cultures of MDA-MB-453 shScr and shFGFR4 cells. In 2D, FGFR4
silencing did not consistently alter YAP S127 phosphorylation or nuclear localization, which both varied depending on the level of serum and cell confluency ( Fig. S4A-E) . Although the nuclear/cytoplasmic intensity ratio remained essentially unaltered (Fig. S4F ), FGFR4 silencing increased the inactive YAP pS127 relative to total YAP in the 3D spheres (Fig. 5A) . Moreover, dispersed YAP localization in shScr spheres shifted to a pattern of membrane-proximal YAP after FGFR4 silencing, coincident with increasingly polarized cell architecture and epithelial-like junctions (Fig. 5B) .
To obtain a further unbiased view of the identified functional link between FGFR4 and Hippo pathway in human breast cancer, we systematically analyzed (phospho)protein alterations upon FGFR4 overexpression using TCGA reverse phase protein array (RPPA) data. The most significant alteration associated with FGFR4 overexpression was the decreased progesterone receptor expression (Fig. 5C) . Consistent with the co-expression with HER2 mRNA, FGFR4 overexpression likewise correlated with increased total and pY1248 HER2 (ERBB2), as well as EGFR pY1068 and ERBB3 pY1248 in conjunction with adverse patient outcome ( Fig. 5C, S4G ; TCGA [4] ). Significantly, YAP pS127 was downregulated in the FGFR4 overexpressing tumors (Fig. 5C) , supporting the FGFR4 function in promoting aggressive properties in human HER2 + breast cancer by down-regulation of both MST1/2 and YAP in 3D microenvironment.
Discussion
Apoptosis evasion is one of the classical hallmarks of cancer. In this study, we identified the apoptosis-promoting MST1/2, together with the other Hippo pathway proteins CSNK1D and PRKCI, among the top five FGFR4 substrates based on Z-score in an unbiased in vitro screen. We further provide evidence suggesting that the FGFR4-dependent MST1 Y433 phosphorylation inhibited MST1/2 activity. In the endogenous FGFR4 + /HER2 + breast cancer cell model, this inhibition was essential to counteract the induction of MST1/2-dependent, stress-associated apoptosis. This suggests that by the identified mechanism, FGFR4 increases the cancer cell survival potential in these breast tumors, where proliferation is driven by HER/ERBB as well as FGFR4 signaling [4, 5] . Additionally supporting this conclusion, FGFR4 overexpression was associated with poor outcome of the HER2 + breast cancer patients.
MST1 and MST2 (orthologs of Drosophila Hippo) are the core kinases of the Hippo signaling pathway. However, the complex and highly context-dependent regulatory mechanisms of mammalian Hippo pathway in health and disease still remain incompletely understood. What is known is that the MST1/2 are activated via homo-or heterodimerization followed by trans-phosphorylation at T183/180 [17, 44] . Upon apoptosis, caspase-3-mediated cleavage removes the C-terminal regulatory and nuclear export signals of MST1/2, triggering nuclear translocation of the active N-terminal serine/threonine kinase [18, 19] . Although MST1 overexpression has previously been implicated in histone phosphorylation and chromatin condensation [19, 45] , the contribution of endogenous MST1/2 to apoptosis, downstream of caspase-3 activation, has remained unclear [17] . In this study, screen (data not shown). Of note, the other herein identified unique MST1 phosphosite pS410 was detected only in the absence of FGFR4 activity and pY433, raising the possibility of mutually regulated phosphorylation of these MST1 residues. The two MST1 phosphosites detected independently of pY433 and FGFR4 have also been characterized previously; MST1 S320 as a phosphorylation site for anti-apoptotic CK2 [52] , and T177 as a MST1 activity -dependent site [53] .
Therefore, the specific net effects of all the MST1 phosphosites on its activity regulation, including context-dependent contributions by kinases other than FGFR4, will be of interest. Nevertheless, our current results show that the active FGFR4 tyrosine kinase phosphorylates and inactivates the proapoptotic MST1/2 serine/threonine kinase in breast cancer cells, thus revealing a novel mechanism of RTK-mediated apoptosis evasion and oncogenic FGFR4 function in cancer.
Apart from the direct pro-apoptotic nuclear functions, MST1/2 act on canonical Hippo signaling, which negatively regulates the oncogenic YAP activity by serine phosphorylation and cytoplasmic retention [17, 54] . In cancer, however, the non-canonical regulation of YAP expression, localization and activity frequently prevails in conjunction with the loss of balancing feed-back mechanisms of normal cellular homeostasis [16, 54, 55] . Therefore, we tested the hypothesis that FGFR4-mediated attenuation of MST1/2 activity could canonically suppress YAP phosphorylation and cytoplasmic retention, thus increasing the nuclear YAP. Indeed, YAP pS127 was increased in FGFR4 knockdown 3D cell spheres, and decreased in the FGFR4-overexpressing human HER2 + breast cancers in TCGA RPPA data. The multidimensional microenvironment seems crucial for this, as in 2D cell cultures the FGFR4-mediated MST1/2 suppression did not correlate with YAP S127 phosphorylation or nuclear translocation. This is consistent with accumulating evidence indicating that factors such as cell polarity, junctional complexes, and cytoskeletal signals are important in YAP regulation even independent of MST1/2 [15, 48] . An interesting further aspect for these cellular regulatory mechanisms comes from the findings that FGFR1, -2, and -4 are direct transcriptional targets of YAP, and a feed-forward loop has been described between YAP and FGFR signaling at least in cholangiocarcinoma and ovarian cancer [56, 57] .
In conclusion, the identified oncogenic FGFR4 activity explains mechanistically how RTKs such as with FGFR4 upregulation in breast cancer, visualized using cBioPortal [38, 39] . The four most significantly up-and downregulated proteins are highlighted (red dots); ERBB2, alternative name of HER2; PR, progesterone receptor. 
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